Journals LibraryNHS NIHR - National Institute for Health Research
HTA - 06/303/98
PERSEPHONE - duration of trastuzumab study with chemotherapy in early breast cancer: six versus twelve months
Project title: PERSEPHONE - duration of trastuzumab study with chemotherapy in early breast cancer: six versus twelve months
Call to action: 06/303 HTA Clinical Trials - Pharmaceutical Panel
Research type: Primary Research
Contractor: University of Cambridge
Started: April 2007 | Status: Published September 2020
This trial showed that in patients with HER2-positive early breast cancer, 6 months' adjuvant trastuzumab was non-inferior to 12 months', with less cardiac toxicity and fewer severe adverse events.
Links to project documentation
The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.